Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome

Head and Neck

Volumn 33, Issue 10, 2011, Pages 1387-1393

  Ganly, Ian ^a   Bocker, Jennifer ^a   Carlson, Diane L ^a   D'Arpa, Salvatore ^a   Coleman, Maria ^a   Lee, Nancy ^a   Pfister, David G ^a   Shah, Jatin P ^a   Patel, Snehal G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

chemoradiation; neck dissection; prognosis; viable tumor

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VIABILITY;

CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK DISSECTION; PHARYNGEAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 80052985870     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21612     Document Type: Article

References (35)

1. Corry J, Peters L, Fisher R, et al. N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders-results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck 2008; 30: 737-742.
2. Lau H, Phan T, Mackinnon J, Matthews TW,. Absence of planned neck dissection for the N2-N3 neck after chemoradiation for locally advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck 2008; 134: 257-261.
3. Rengan R, Pfister DG, Lee NY, et al. Long term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer. Am J Clin Oncol 2008; 31: 465-469.
4. Clayman GL, Johnson CJ, Morrison W, Ginsberg L, Lippman SM,. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck 2001; 127: 135-139.
5. Argiris A, Stenson KM, Brockstein BE, et al. Neck dissection in the combined modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck 2004; 26: 447-455.
6. Corry J, Rischin, Smith JG, et al. Radiation with concurrent late chemotherapy intensification ("chemoboost") for locally advanced head and neck cancer. Radiother Oncol 2000; 54: 123-127.
7. Lavertu P, Adelstein DJ, Saxton JP, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck 1997; 19: 559-566.
8. Sewall GK, Palazzi-Churas KL, Richards GM, Hartig GK, Harari PM,. Planned postradiotherapy neck dissection: Rationale and clinical outcomes. Laryngoscope 2007; 117: 121-128.
9. Gourin CG, Williams HT, Seabolt WN, Herdman AV, Howington JW, Terris DJ,. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope 2006; 116: 705-710.
10. Brizel DM, Prosnitz RG, Hunter S, et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head and neck cancer. Int J Radiat Oncol Biol Physiol 2004; 58: 1418-1423.
11. Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Surg 2000; 126: 950-956.
12. Mukhija V, Gupta S, Jacobson AS, Anderson Eloy J, Genden EM,. Selective neck dissection following adjuvant therapy for advanced head and neck cancer. Head Neck 2009; 31; 183-188
13. Sandhu A, Rao N, Giri S, et al. Role and extent of neck dissection for persistent nodal disease following chemoradiation for locally advanced head and neck cancer: how much is enough. Acta Oncol 2008; 47: 948-953.
14. Yeung AR, Liauw SL, Amdur RJ, et al. Lymph node positive head and neck cancer treated with definitive radiotherapy. Cancer 2008; 112: 1076-1082.
15. Robbins KT, Shannon K, Vieira F,. Superselective neck dissection after chemoradiation: feasibility based on clinical and pathologic comparisons. Arch Otolaryngol Head Neck 2007; 133: 486-489.
16. Lango MN, Andrews GA, Ahmad S, et al. Postradiotherapy neck dissection for head and neck squamous cell carcinoma: pattern of pathologic residual carcinoma and prognosis. Head Neck 2009; 31: 328-337.
17. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125: 362-366.
18. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010; 16: 1226-1235.
19. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
20. Lindquist D, Romanitan M, Hammarstedt L, et al. Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 2007; 1: 350-355.
21. Ong SC, Schöder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008; 49: 532-540.
22. Sasslet AM, Esclamado RM, Wolf GT,. Surgery after organ preservation therapy. Analysis of wound complications. Arch Otolaryngol Head Neck Surg 1995; 121: 162-165.
23. Lavertu P, Bonafede JP, Adelstein DJ, et al. Comparison of surgical complications after organ preservation therapy in patients with stage III and IV squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 1998; 124: 401-406.
24. Davidson BJ, Newlark KA, Harter KW, et al. Complications from planned, posttreatment neck dissections. Arch Otolaryngol Head Neck Surg 1999; 125: 401-405.
25. Morgan JE, Breau RL, Suen JY, et al. Surgical wound complications after intensive chemoradiotherapy for advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2007; 133: 10-14.
26. Donatelli-Lassig AA, Duffy SA, Fowler KE, Ronis DL, Chepeha DB, Terrell JE,. The effect of neck dissection on quality of life after chemoradiation. Otolaryngol Head Neck Surg 2008; 139: 511-518.
27. Berlangieri SU, Brizel DM, Scher RL, et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck 1994; 16: 340-346.
28. 18F) fluorothymidine. Methods 2009; 48: 205-215.
29. Mankoff DA, Eary JF,. Proliferation imaging to measure early cancer response to targeted therapy. Clin Cancer Res 2008; 14: 7159-7160.
30. Bading JR, Shields AF,. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008; 49 (Suppl): 64S-80S.
31. Garcia C, Flamen P,. Role of positron emission tomography in the management of head and neck cancer in the molecular therapy era. Curr Opin Oncol 2008; 20: 275-279.
32. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol 2005; 77: 18-24.
33. Schoder H, Fury M, Lee N, Kraus D,. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009; 50: 74-88.
34. Cao Y, Popovtzer A, Li D, et al. Early prediction of outcome in advanced head and neck cancer based on tumor blood volume alterations during therapy: a prospective study. Int J Radiation Oncology Biol Physiol 2008; 72: 1287-1290.
35. Palambo B,. Brain tumor recurrence: brain single-photon emission computed tomography, PET and proton magnetic resonance spectroscopy. Nucl Med Commun 2008; 29: 730-735.